UICC World Cancer Congress 2026 Exhibitor List

Prof. Jeff Dunn AO is Chief of Mission and Head of Research at the Prostate Cancer Foundation of Australia. He is also Professor of Social and Behavioural Science and Chair of Cancer Survivorship at the University of Southern Queensland. He is a Board Member and Chair of the Audit and Risk Committee for the West Moreton Hospital and Health Service. He served as President of the Union for International Cancer Control from 2022 to 2024. His work in cancer control spans 30 years, in which time he has dedicated his career to the development of strategies that underpin cancer survival and improve awareness of the disease with a special focus on the social and behavioural aspects of cancer and has over 200 publications, including peerreviewed manuscripts, chapters, books and reports. In 2014 Jeff was appointed an Officer in the Order of Australia for distinguished service to medical administration through leadership of cancer control organisations and promotion of innovative and integrated cancer care programmes.

Prof. Anne Lee is currently the Vice-Chairman of Hong Kong Anti-Cancer Society. In addition, she serves as Chief of Service of the Center of Clinical Oncology at the University of Hong Kong - Shenzen Hospital. She is also an Adjunct Professor at the Medical Faculty of Universitas Indonesia. Prof Lee is an Honorary Professor at the University of Hong Kong. She serves as Hong Kong Ambassador at the World Cancer Research Fund and as Coordinator of UICC's TNM Global Advisory Group. In addition to her professional qualification as Fellow of the Royal College of Radiologists in Clinical Oncology (United Kingdom) and Fellow of the Hong Kong Academy of Medicine, she was conferred Doctor of Medicine by the University of Hong Kong in 2008, and was awarded the Sir Patrick Manson Gold Medal. She has been the President of Hong Kong Head and Neck Society and Chairman of Hong Kong Nasopharyngeal Cancer Study Group. Currently she is the Vice President of Hong Kong College of Radiologists. Dr. Lee's main research contributions focus on nasopharyngeal cancer. She serves in editorial board of many international journals. She also serves in many international academic organizations, including being the Coordinator of the Global Advisory Group and a member of TNM Expert Advisory Panel on Head and Neck Cancers for the Union for International Cancer Control. Dr. Lee has received many honors. She was awarded Gilbert H. Fletcher Distinguished Professor Lecturer by The University of Texas, M.D. Anderson Cancer Center, United States, in 2009, Honorary Membership by the European Society for Radiotherapy & Oncology in 2012, Honorary Membership by the Radiological Society of North America in 2013, and Wharton Lecturer by Princess Margaret Cancer Centre, Canada, in 2015.

Dr. Miriam Mutebi is a Consultant Breast Surgical Oncologist and Assistant Professor in the Department of Surgery at the Aga Khan University Hospital in Nairobi, Kenya. She is also a clinical epidemiologist and health systems researcher with a research focus on understanding barriers to access for women with cancers in Sub-Saharan Africa and in designing interventions to mitigate those barriers. She is a member of the UICC Board of Directors for the term 2024-2026. She is the President of the African Organization for Research and Training in Cancer (AORTIC), Immediate Past president for the Kenya Society of Haematology and Oncology (KESHO) and on the board of directors of the Union for International Cancer Control (UICC). She is also the co-founder of the Pan African Women’s Association of Surgeons which was developed to mentor and provide transformative leadership for women in surgery in order to improve surgical care and pathology on the continent and is part of the Kenya Association of Women Surgeons. She is the Co-chair of the National Cancer Taskforce in Kenya, Chair of the Commonwealth Taskforce for the elimination of Cervical Cancer and a commissioner with 5 Lancet commissions including Women, Power and Cancer, Cancer in sub-Saharan Africa and Breast Cancer. She is the recipient of the ASCO 2024 Humanitarian Award for going above and beyond the call of duty in providing outstanding patient care through innovative means and exceptional service and leadership. She is currently pursuing a pilot's licence in order to extend breast care services to marginalised areas.

As Director of Platform Architecture and Cloud Architecture Lead for APJ, LATAM, and MEA at Teradata, Christopher Jackson spearheads the company's cloud and AI initiatives across a vast and diverse international landscape. He directs a team of expert cloud architects responsible for supporting sales and account teams across all industries. His primary focus is on accelerating the customer adoption of Teradata Vantage, and driving innovation through the integration and adoption of agentic AI solutions, empowering organizations to unlock new value from their trusted data.

Rina Hui is a Clinical Professor and the Director of the Centre of Cancer Medicine at the University of Hong Kong. She has a clinical and research focus on breast and lung cancers. Rina also serves as a member of the Senate, a member of the Honorary Fellowships Committee and chairs the Committee of Discontinuation at the University of Hong Kong. Rina is a steering committee member of the Hong Kong Breast Cancer Registry and a council member of the Hong Kong Cancer Therapy Society. After completing her medical degree at The University of Sydney and specialist training at the Royal North Shore Hospital, Rina undertook translational research in cyclin D1-CDK4/6-p16 INK4a -pRb pathway in breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Before joining HKU in January 2023, Rina was a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at Westmead Hospital, Australia. She previously served as Co-chair of Oncology Block at the Sydney Medical School, the University of Sydney and served in the written examination committee for the Royal Australasian College of Physician. She was the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Basic Sciences of Oncology Course Subject Matter Expert Group. Rina serves on the Education Committee for International Association for the Study of Lung Cancer (IASLC) and was a member of the scientific program committee for European Society of Medical Oncology Congress in 2021 and 2022. Rina has been principal investigator on many clinical trials, including phase I as well as many landmark practice-changing phase III clinical studies of immunotherapy and targeted therapies in breast and lung cancers, resulting in publications in highly ranked journals.